Biognosys

Biognosys is a leading provider of advanced mass spectrometry-based proteomics solutions for drug discovery, development, and clinical research. The company's flagship offering, TrueDiscovery, is an unbiased, large-scale proteomics platform that enables deep profiling of tissue and biofluids proteomes with exceptional specificity and reproducibility. Powered by Hyper Reaction Monitoring (HRM) mass spectrometry, a patented Data Independent Acquisition (DIA) technology, TrueDiscovery quantifies thousands of proteins, including an unlimited number of proteoforms, in a single experiment.

Biognosys' proprietary P2 Plasma Enrichment method, launched in May 2024, is a groundbreaking technology that achieves market-leading performance for unbiased, deep plasma proteomics. By leveraging a novel single-well, single particle-type enrichment approach, P2 enriches low-abundant proteins while effectively depleting highly abundant plasma proteins. This method enables the quantification of up to 7,000 proteins in plasma, with a remarkable 10-fold enrichment factor compared to untreated plasma samples.

The company's TrueTarget platform, based on limited proteolysis-coupled mass spectrometry (LiP-MS), is designed for identifying on- and off-target binding effects, elucidating mechanisms of action, and revealing potential toxicities in early drug discovery stages. Additionally, the TrueSignature platform provides high-precision, customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.

Biognosys' solutions leverage high-resolution mass spectrometry to quantify proteins with industry-leading precision, depth, and throughput. The company's strategic partnership with Bruker further expands its global reach and accessibility to advanced proteomics technologies.

Key customers and partnerships

In April 2024, Biognosys forged a strategic partnership with Alamar Biosciences to offer Alamar's ultra-sensitive NULISA assays for low-abundance proteins alongside Biognosys' unbiased DIA-MS analysis. This integrated approach aims to provide a comprehensive view of the plasma proteome, enabling the quantification of both high- and low-abundance proteins.

Furthermore, as a result of the partnership with Bruker announced in January 2023, Biognosys plans to establish an advanced proteomics contract research organization (CRO) services laboratory in the US, leveraging Bruker's timsTOF platform to offer customers access to multiple mass spectrometry technologies.